Retatrutide, developed by Soma Chems , is gaining increasing attention as a novel method for obesity control . This innovative drug integrates the activity of a GLP-1 receptor agonist and a GIP receptor stimulant, intended to simply promote metabolic improvements but also improve underlying metab